Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bio-Rad Laboratories, Inc. Class A Common Stock (NY:BIO)

365.49 +9.92 (+2.79%)
Delayed Quote Updated: 11:37 AM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bio-Rad Laboratories, Inc. Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Bio-Rad Laboratories Bets on Digital PCR, Margins and Smarter M&A Growth ↗
Bio-Rad Laboratories (NYSE:BIO) is pursuing a multi-year effort to improve growth, expand margins and strengthen free cash flow, with management emphasizing portfolio focus, operating discipline and a... 
Via MarketBeat
News headline image
Bio-Rad to Participate in Fireside Chat During Bernstein Insights Healthcare Leaders and Disruptors 3rd Annual Forum
From Bio-Rad Laboratories, Inc.
Via Business Wire
News headline image
Bio-Rad to Participate in Fireside Chat During Wells Fargo’s 21st Annual Healthcare Conference
From Bio-Rad Laboratories, Inc.
Via Business Wire
News headline image
Bio-Rad (BIO) Q2 2026 Earnings Call Transcript ↗
Digital PCR revenue surged over 20% as clinical diagnostics grew. 
Via The Motley Fool
Topics Earnings
Bio-Rad (NYSE:BIO) Falls After Q2 Beat as Life Science Sales Weigh ↗
Via Chartmill
Bio-Rad Q1 2026 Revenue Misses Estimates, Outlook Cut as NYSE:BIO Faces Cautious Trading ↗
Via Chartmill
News headline image
Bio-Rad Laboratories Q2 Earnings Call Highlights ↗
Bio-Rad Laboratories (NYSE:BIO) reported second-quarter revenue of approximately $651 million, essentially flat from $652 million a year earlier on a reported basis and down 1.9% on a currency-neutral... 
Via MarketBeat
Topics Earnings
News headline image
Bio-Rad Reports Second-Quarter 2026 Financial Results
From Bio-Rad Laboratories, Inc.
Via Business Wire
News headline image
Bio-Rad to Report Second-Quarter 2026 Financial Results on Tuesday, August 4, 2026
From Bio-Rad Laboratories, Inc.
Via Business Wire
News headline image
Bio-Rad vs. Charles River Labs: Which Medical Research Stock Is a Better Buy in 2026? ↗
Bio-Rad posts robust margins and liquidity, while Charles River leads in global drug discovery services. Explore how their fundamentals stack up for investors. 
Via The Motley Fool
Bio-Rad Laboratories (NYSE:BIO) Stock Plummets 12% After Q4 Earnings Miss and Weak 2026 Outlook ↗
Via Chartmill
Topics Earnings
News headline image
Earnings Scheduled For October 29, 2025 ↗
 
Via Benzinga
News headline image
Why Elliott Sees Hidden Billions Inside Bio-Rad Laboratories ↗
Elliott Management builds a stake in Bio-Rad (NYSE: BIO) to push for better performance, but family voting control could pose a hurdle. 
Via Benzinga
News headline image
Bio-Rad to Participate in Upcoming Investor Conferences
From Bio-Rad Laboratories, Inc.
Via Business Wire
News headline image
Bio-Rad (BIO) Q2 2025 Earnings Call Transcript ↗
Bio-Rad (BIO) Q2 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Bio-Rad (BIO) Q1 2026 Earnings Transcript ↗
Bio-Rad (BIO) Q1 2026 Earnings Transcript 
Via The Motley Fool
Topics World Trade
News headline image
Bio-Rad Reports First-Quarter 2026 Financial Results
From Bio-Rad Laboratories, Inc.
Via Business Wire
News headline image
Bio-Rad to Report First-Quarter 2026 Financial Results on Thursday, April 30, 2026
From Bio-Rad Laboratories, Inc.
Via Business Wire
News headline image
Bio-Rad (BIO) Q4 2025 Earnings Call Transcript ↗
Bio-Rad (BIO) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Bio-Rad Reports Fourth-Quarter and Full-Year 2025 Financial Results
From Bio-Rad Laboratories, Inc.
Via Business Wire
News headline image
Bio-Rad to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 12, 2026
From Bio-Rad Laboratories, Inc.
Via Business Wire
News headline image
Bio-Rad’s Management to Host Investor Meetings at J.P. Morgan's 44th Annual Healthcare Conference
From Bio-Rad Laboratories, Inc.
Via Business Wire
News headline image
Why a Fund Trimmed a $41 Million CompoSecure Stake Amid a 47% Stock Run ↗
Amid a monster year and, more recently, a transformative deal announcement, this move raises a sharper question about how much upside is really left at today’s valuation. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why a Fund Cut $4 Million of Payoneer Stock Despite Record Revenues ↗
Payoneer just posted record revenue and raised guidance, yet one fund trimmed its stake. The disconnect is where the real story is. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why Bio-Rad Laboratories Stock Slipped by More Than 3% on Thursday ↗
The company doesn't seem like it will generate pops in key fundamentals anytime soon. 
Via The Motley Fool
Topics Supply Chain
News headline image
Bio-Rad Reports Third-Quarter 2025 Financial Results
From Bio-Rad Laboratories, Inc.
Via Business Wire
News headline image
Bio-Rad to Report Third Quarter 2025 Financial Results on Wednesday, October 29, 2025
From Bio-Rad Laboratories, Inc.
Via Business Wire
News headline image
Thermo Fisher Scientific Soars on Strategic Wins, Market Optimism
Thermo Fisher Scientific Inc. (NYSE: TMO) experienced a robust surge in its stock value today, October 1, 2025, climbing an impressive 9.79% as market optimism swelled around a series of recent... 
Via MarketMinute
Topics Artificial Intelligence Economy Government
News headline image
Bio-Rad Laboratories, Inc. Co-Founder and Director Emeritus Alice Schwartz Passes Away
From Bio-Rad Laboratories, Inc.
Via Business Wire
News headline image
Bio-Rad's Management to Participate in Upcoming Investor Conferences
From Bio-Rad Laboratories, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.